Daily Delivery Channel Intrommune's Oral Mucosal Immunotherapy OMIT platform is designed to be used during brushing, establishing a daily habit that can drive adherence and ongoing utilization. This creates sales opportunities with oral care brands, dental clinics, and consumer health retailers for co marketing, co branding, and integrated patient education. The INT301 toothpaste program reinforces the delivery channel and offers a potential co branded product line for over the counter and in clinic sale.

Clinical Partnerships As a clinical stage company with Phase 1 data being presented, Intrommune is positioned to attract CRO/CDMO partners and potentially pharma investors to accelerate development and manufacturing. These collaborations can unlock access to trial sites, regulatory expertise, and distribution networks, creating near term sales opportunities through licensing or co development deals. Engaging with partners for patient access strategies and payer readiness can also speed market entry.

Market Opportunity The first product targets peanut allergy with a large global addressable market and sizable US segment, creating demand among allergists, pediatricians, hospitals, and specialty pharmacies. This landscape supports opportunities to tailor evidence packages for payer negotiations, form strategic alliances with hospital systems, and build advocacy channels through professional societies. A clear path to payer coverage can drive faster uptake and durable revenue.

Strategic Leadership Recent board and leadership appointments signal a capability to scale operations, secure funding, and advance regulatory milestones. This makes Intrommune an attractive partner for licensing, co development, or distribution deals with larger biotech or pharmaceutical players seeking to expand their immunotherapy portfolio. The leadership momentum can shorten sales cycles with potential customers and channel partners.

Platform Expansion Beyond peanut allergy the OMIT platform has potential to address other food allergies, expanding the total addressable market. The cross over with consumer products through the toothpaste program creates hybrid go to market opportunities with consumer health channels and dental practices. Pursuing licensing or strategic collaborations around platform expansion can generate multiple revenue streams.